Rising Incidence of Cervical Cancer Dialing Growth for Cervical Cancer Diagnostic Tests Market, states TMR

The competitive landscape of the global cervical cancer diagnostic tests market includes players such as F.Hoffmann-La Roche Ltd., Hologic Inc., Abbott Laboratories, Quest Diagnostics, and Becton, Dickinson & Company. Despite the highly fragmented nature of the market, top players dominate the market, observes Transparency Market Research. This is because top companies are involved in devising intense competitive strategies and ploughing back profits into research and development.

“Strategic acquisitions are on the growth charts of top players in the global cervical cancer diagnostic tests market,” points out a TMR analyst. A case in point is Abbott Laboratories. In June 2014, Abbott Laboratories announced a factual agreement to acquire a Veropharm, which is a leading Russia-based pharmaceutical company. This acquisition would allow Abbott Laboratories to obtain Veropharm’s large portfolio of medicines, which are targeted towards its current pharmaceutical therapeutic areas.

Focus on product differentiation is another key growth model that leading players in this market are adopting to gain competitive advantage. Top players are also seeking approval for the commercialization of existing assays in the bid to enhance their offerings.

View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=736

Lack of Knowledge about Women’s Diseases in Developing Countries Hampers Market Growth

A TMR analyst says, “Increasing rate of prevalence of cervical cancer is expected to fuel the growth of the global cervical cancer diagnostic tests market.” According to the data presented by the American Cancer Society, cervical cancer accounts for a large number of cancer deaths in women in the U.S. However, as per several studies carried out by the Centers for Disease Control and Prevention, new cases of cervical cancer and deaths due to cervical cancer have dropped significantly over the last couple of years.

High incidence of human papillomavirus (HPV) is likely to fuel the market’s growth in the coming years. An increasing awareness about cervical cancer screening is assisting in accelerating the growth of this market.

“Lack of proper primary healthcare infrastructure and outdated facilities in most developing countries pose major challenges to the growth of the global cervical cancer diagnostic tests market,” says a TMR analyst. Due to the lack of primary healthcare facilities in developing nations such as Brazil, India, and China, patients seek treatment from hospitals, which are considerably high in cost. As such, many patients evade screening to avoid high hospitalization costs.

Lack of awareness about women’s diseases in most of the developing regions is a reason for high female mortality in these regions. The majority of women in these regions do not have knowledge about cervical cancer and the regular screening that should be undertaken for its early detection.

Pap Test Type Accounts for Significant Market Share

The global cervical cancer diagnostic tests market is expected to reach a valuation of US$8.9 bn by 2020, says the study.

By test type, Pap test held more than 45% of the market in 2013. The growth of this segment is mainly attributed to the rising awareness about cancer diagnosis and the high efficacy of the investigation at relatively low costs. HPV testing is expected to register a significant growth rate between 2014 and 2020, adds the study. Asia Pacific is expected to emerge as a significant market for cervical cancer diagnostic tests due to the easy penetration of service providers, rising disposable incomes, and an increasing knowledge about women’s diseases.

The information presented in this review is based on a report from Transparency Market Research titled “Cervical Cancer Diagnostic Tests Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020.”

Cervical Cancer Diagnostic Tests Market - Global Industry Analysis Report, 2014 - 2020

Cervical cancer is the third most common cancer among women and has become the second most common cause of cancer-related deaths across the globe. The deadly disease accounts for around 300,000 deaths annually. Appropriate screening methods and diagnostic tests help in early detection of cervical cancer. The global cervical cancer diagnostic tests market is estimated to expand at a CAGR of 6.10% during the period between 2014 and 2020. The overall market was worth US$5.9 bn in 2013 and is expected to reach a valuation of US$8.9 bn by 2020.

Browse Full Report: http://www.transparencymarketresearch.com/cervical-cancer-diagnostic-tests-market.html

Diagnostic Tests in High-Income Nations Curbing Occurrence of Cervical Cancer

One of the most common risk factors for cervical cancer is infection by the human papilloma virus (HPV). Other risk factors include smoking, Chlamydia infection, long-term use of oral contraceptives, family history of cervical cancer, and others. HPV testing, Pap smear tests, endocervical curettage (ECC), cone biopsy, loop electrosurgical excision procedure (LEEP), and colposcopy are some of the commonly used diagnostic tests for cervical cancer. In 2013, Pap smear tests accounted for more than 45% of the global cervical cancer diagnostic tests market owing to the high efficacy of the tests at relatively low costs. However, the low cost of Pap smear tests has not helped to decrease the number of patients affected with cervical cancer across lower income countries.

According to a new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, the prevalence of infection-related cancers such as stomach, liver, and cervical cancers as well as lung, breast, and colorectal cancers has increased in low- and middle-income countries. The increasing prevalence of cervical cancer is a major concern across Southeast Asia, Sub-Saharan Africa, Central and Eastern Europe, and Latin America and the Caribbean. In high-income nations, screening programs implemented years ago have helped to curb cervical cancer rates by as much as 4% annually.

Cervical Cancer Prevention Program in Haiti: A Concrete Step to Fight the Disease

In Haiti, around 3,000 women get cervical cancer each year and almost half of them die from the illness. In fact, the country registers the highest rate of cervical cancer across the world. Partners in Health, a Boston-based non-profit organization, has launched a two-year pilot program in Haiti to screen 20,000 women for cervical cancer and vaccinate around 6,000 girls against the strains of human papilloma virus. Zanmi Lasante, the Haitian program of Partners in Health, plans to reach around to 60,000 people, making them aware about the disease.

Request For Custom Research: http://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=736

In the near future, the global cervical cancer diagnostic tests market is expected to gain impetus from the demand arising from low- and middle-income countries. Though these countries lack resources to fight against the disease, development of cervical cancer prevention strategy along with donation of vaccines and other supplies will help to decrease the prevalence of the disease. For example, in Haiti, the U.S. Agency for International Development is supporting the pilot program launched by Zanmi Lasante. To avail vaccines and other supplies for the patients, the non-profit organization is coordinating with drug manufacturing company Merck & Co.

Wide Adoption of HPV and Pap Smear Tests to Drive Cervical Cancer Diagnostic Tests Market at 6.10% CAGR till 2020

Cancer Care Manitoba demonstrated cancer testing procedures at Winnipeg’s Health Science Centre (HSC) recently, as part of the cervical cancer awareness week. The main focus of this program was to exhibit liquid-based cytology testing. Liquid-based cytology testing is a process that reduces the need for retesting. Samples of cervical cancer are collected through a process called pap test. This method of collecting samples of cervical cancer allows accurate and quick analysis.

In Manitoba, every year, nearly 45 women are identified with cervical cancer and the number is growing rapidly. 80% of cervical cancer cases can be basically prevented by regular screening. Sharon Blady, the minister of health, was present at the Health Science Centre, where various testing methods for cervical cancer were addressed and demonstrated. According to the CervixCheck program, every sexually active women should receive a pap test once every three years, right from the age of 21.

Pap Smear Test Sector to Expand at 6.0% CAGR till 2020

The global cervical cancer diagnostic tests market was valued at US$5.9 bn in 2013 and is expected to reach US$8.9 bn by 2020. The increasing number of cancer patients is expected to propel the global cervical cancer diagnostic tests market at a 6.10% CAGR during the period from 2013 to 2020.

The global cervical cancer diagnostic tests market is segmented on the basis of the type of tests performed and geography. By the type of test, the global cervical cancer diagnostic tests market is classified into HPV testing, pap smear tests, colposcopy, and endocervical curettage procedure. In 2013, the HPV testing sector dominated the global cervical cancer diagnostic tests market. The increasing incidence of HPV infection and increasing number of people who smoke is expected to drive the HPV testing sector during the forecast period. The pap smear test sector is predicted to expand at a 6.0% CAGR till 2020 due to the possibility of early detection of cell abnormalities through this test. Demand for other types of tests such as LEEP and ECC is also expected to increase steadily.

Get Free Sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=736

North America to Account for Highest Global Market Share

By geography, the global cervical cancer diagnostic tests market is classified into North America, Asia Pacific, Europe, and Rest of the World. In 2013, the global cervical cancer diagnostic tests market was led by the North America regional cervical cancer diagnostic tests market. The Asia Pacific regional segment is predicted to register the highest market share by the end of the forecast period due to factors such as easy market penetration, low labor costs, and tax benefits. Some of the prominent players in the global cervical cancer diagnostic tests market are Becton, Hologic, Inc., Guided Therapeutics, Abbott Laboratories, Dickinson and Company, Guided Therapeutics, OncoHealth Corp., Roche Diagnostics, Zilico Ltd., Quest Diagnostics, Inc., and QIAGEN.